Stockscreener 앱 받기
9.34
0.80%
-0.07
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Karyopharm (NASDAQ: KPTI) registers resale of 8.843M shares from private placement - Stock Titan
Karyopharm Therapeutics: Selling stockholder may resell up to 8,843,036 shares of Karyopharm common stockSEC filing - marketscreener.com
Karyopharm Therapeutics: Selling Stockholder May Resell Up To 8,843,036 Shares Of Karyopharm Common StockSEC Filing - TradingView
Karyopharm Therapeutics may offer up to $400 million in securitiesSEC filing - marketscreener.com
Karyopharm Therapeutics (NASDAQ: KPTI) files $400M shelf, $100M ATM with Jefferies - Stock Titan
Karyopharm (KPTI) Q1 2025 Earnings Transcript - AOL.com
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
KPTI stock down on mixed phase III myelofibrosis combo study data - MSN
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
Karyopharm Therapeutics (KPTI) price target increased by 13.33% to 13.87 - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Piper Sandler Reiterates Overweight Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
KPTI Upgraded by Piper Sandler -- Price Target Raised to $16.00 - GuruFocus
Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $16 - Moomoo
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
Karyopharm Therapeutics (KPTI) price target decreased by 22.08% to 12.24 - MSN
Is Karyopharm Therapeutics (KPTI) stock considered a safe play | Q4 2025: Below ExpectationsPricing Power - Cổng thông tin điện tử tỉnh Lào Cai
Karyopharm (KPTI) CMO logs pre-planned tax-related sale of 449 shares - Stock Titan
Karyopharm’s myelofibrosis trial selected for ASCO presentation By Investing.com - Investing.com Australia
Karyopharm’s myelofibrosis trial selected for ASCO presentation - Investing.com
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting - Karyopharm
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Is Karyopharm Therapeutics (KPTI) stock a smart investment today (Bullish Sentiment) 2026-04-20Risk Reward Ratio - Cổng thông tin điện tử tỉnh Lào Cai
RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance - Insider Monkey
KPTI SEC FilingsKaryopharm Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Karyopharm Therapeutics : Corporate Presentation - marketscreener.com
0.78%
3.01%
자본화:
|
볼륨(24시간):